SG11201403997SA - Dual antigen-induced bipartite functional complementation - Google Patents
Dual antigen-induced bipartite functional complementationInfo
- Publication number
- SG11201403997SA SG11201403997SA SG11201403997SA SG11201403997SA SG11201403997SA SG 11201403997S A SG11201403997S A SG 11201403997SA SG 11201403997S A SG11201403997S A SG 11201403997SA SG 11201403997S A SG11201403997S A SG 11201403997SA SG 11201403997S A SG11201403997S A SG 11201403997SA
- Authority
- SG
- Singapore
- Prior art keywords
- functional complementation
- dual antigen
- induced bipartite
- bipartite functional
- induced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12151125 | 2012-01-13 | ||
PCT/EP2013/050603 WO2013104804A2 (fr) | 2012-01-13 | 2013-01-14 | Complémentation fonctionnelle bipartite induite par un antigène double |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201403997SA true SG11201403997SA (en) | 2014-08-28 |
Family
ID=47715984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403997SA SG11201403997SA (en) | 2012-01-13 | 2013-01-14 | Dual antigen-induced bipartite functional complementation |
Country Status (25)
Country | Link |
---|---|
US (3) | US20150079093A1 (fr) |
EP (3) | EP3333190A1 (fr) |
JP (1) | JP6408915B2 (fr) |
KR (2) | KR102100817B1 (fr) |
CN (2) | CN108034006A (fr) |
AU (1) | AU2013208895B2 (fr) |
CA (1) | CA2861003C (fr) |
CY (1) | CY1119928T1 (fr) |
DK (1) | DK2802607T3 (fr) |
EA (1) | EA033947B1 (fr) |
ES (1) | ES2653287T3 (fr) |
HK (1) | HK1200175A1 (fr) |
HR (1) | HRP20171912T1 (fr) |
HU (1) | HUE035207T2 (fr) |
IL (1) | IL233566B (fr) |
LT (1) | LT2802607T (fr) |
MX (1) | MX359411B (fr) |
NO (1) | NO2802607T3 (fr) |
PL (1) | PL2802607T3 (fr) |
PT (1) | PT2802607T (fr) |
RS (1) | RS56773B1 (fr) |
SG (1) | SG11201403997SA (fr) |
SI (1) | SI2802607T1 (fr) |
WO (1) | WO2013104804A2 (fr) |
ZA (1) | ZA201405658B (fr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
EP2914286B1 (fr) | 2012-10-30 | 2021-08-18 | Aravax Pty Ltd | Nouvelles molécules immunothérapeutiques et utilisations associées |
RU2689552C2 (ru) | 2013-09-25 | 2019-05-28 | Аравакс Пти Лтд | Новая иммунотерапевтическая композиция и ее применения |
AU2015236054B2 (en) * | 2014-03-25 | 2019-11-21 | Five3 Genomics, Llc | Systems and methods for RNA analysis in functional confirmation of cancer mutations |
EP2985294A1 (fr) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible |
AU2015339032B2 (en) * | 2014-10-31 | 2020-02-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tetravalent TLR9 bispecific antibody |
CN104592391B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
SI3310814T1 (sl) | 2015-06-16 | 2023-11-30 | F. Hoffmann - La Roche Ag | HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO |
EP3112375A1 (fr) * | 2015-07-03 | 2017-01-04 | Ludwig-Maximilians-Universität München | Peptides antigéniques pour le diagnostic, la surveillance d'une thérapie et/ou le traitement du psoriasis vulgaire |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
CA3003304A1 (fr) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Neoepitopes viraux et utilisations de ces derniers |
AU2016358296B2 (en) | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
NZ743881A (en) * | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
US10634680B2 (en) | 2016-04-26 | 2020-04-28 | University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
EA201892693A1 (ru) | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CN105920618A (zh) * | 2016-06-13 | 2016-09-07 | 上海交通大学医学院附属新华医院 | 一种生物靶向纳米基因材料及其制造方法 |
EP3714944A1 (fr) * | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car pour une utilisation dans le traitement de maladie hvg |
CN108085333B (zh) * | 2016-11-14 | 2021-06-29 | 中国科学院分子植物科学卓越创新中心 | 一种延缓薯类植物生理性变质的方法 |
JP6812551B2 (ja) | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原結合タンパク質 |
CA3044729A1 (fr) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Proteines trispecifiques ciblang le psma et procedes d'utilisation |
WO2018136725A1 (fr) * | 2017-01-19 | 2018-07-26 | Harpoon Therapeutics, Inc. | Protéines de liaison inductibles pour les cellules immunitaires innées et méthodes d'utilisation |
US12054544B2 (en) | 2017-02-24 | 2024-08-06 | Chugai Seiyaku Kabushiki Kaisha | Compositions comprising antigen-binding molecules |
WO2018160754A2 (fr) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Protéine monovalente inductible de fixation d' antigène |
CN110678190A (zh) * | 2017-03-28 | 2020-01-10 | 宾夕法尼亚大学董事会 | 保护移植的组织免受排斥的方法 |
IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
AU2018328291B2 (en) | 2017-09-08 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
EP3759135A1 (fr) | 2017-12-21 | 2021-01-06 | Gernot Stuhler | Régime posologique spécifique de thérapie hémicorporelle |
WO2019210848A1 (fr) | 2018-05-03 | 2019-11-07 | Shanghai Epimab Biotherapeutics Co., Ltd. | Anticorps à haute affinité dirigés contre pd-1 et lag-3 et protéines de liaison bispécifiques produites à partir de ceux-ci |
WO2019222547A1 (fr) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition de récepteur par recrutement de phosphatases |
AU2019299434A1 (en) * | 2018-07-02 | 2021-01-07 | The General Hospital Corporation | Antibody tumor-targeting assembly complexes |
BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
CA3120800A1 (fr) * | 2018-12-17 | 2020-06-25 | Revitope Limited | Recruteur de cellules immunitaires jumelles |
EP3934762A1 (fr) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Protéines de liaison à activation conditionnelle limitée |
JP2022530685A (ja) | 2019-05-02 | 2022-06-30 | ザ ジェネラル ホスピタル コーポレイション | Teacおよびattac腫瘍免疫学的組成物および方法 |
JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
WO2021041300A2 (fr) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Anticorps bispécifiques et leurs utilisations |
MX2022009049A (es) * | 2020-01-23 | 2022-11-08 | Exuma Biotech Corp | Receptores de antígenos quiméricos para her2 y métodos de uso de estos. |
EP4097131A1 (fr) * | 2020-01-29 | 2022-12-07 | Merus N.V. | Moyens et procédé permettant de moduler les effets d'engagement de cellules immunitaires |
IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
EP4178985A1 (fr) * | 2020-07-10 | 2023-05-17 | F. Hoffmann-La Roche AG | Anticorps se liant à des cellules cancéreuses et ciblant ces cellules avec des radionucléides |
CN116209680A (zh) | 2020-09-24 | 2023-06-02 | 莫佛塞斯公司 | 与人CD3ε结合的新型人抗体 |
CN112724236B (zh) * | 2021-01-15 | 2022-03-04 | 武汉大学 | 一种两性蛋白1的抗原肽及其抗体与应用 |
EP4377347A1 (fr) | 2021-07-27 | 2024-06-05 | MorphoSys AG | Combinaisons de molécules de liaison à l'antigène |
CN113846115B (zh) * | 2021-09-24 | 2023-10-17 | 广州医科大学 | 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用 |
WO2023183927A2 (fr) | 2022-03-24 | 2023-09-28 | Actinium Pharmaceuticals, Inc. | Anticorps anti-cd45 humanisés |
CN114773452A (zh) * | 2022-04-21 | 2022-07-22 | 谭宏凯 | 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位 |
WO2024026317A2 (fr) * | 2022-07-25 | 2024-02-01 | Vironexis Biotherapeutics Inc. | Vecteurs de virus adéno-associés et leurs procédés d'utilisation pour réduire le risque de métastase et traiter et prévenir une métastase |
CN117305248A (zh) * | 2022-09-09 | 2023-12-29 | 复星凯特生物科技有限公司 | 抗EGFR和cMet双特异性嵌合抗原受体及其应用 |
WO2024104988A1 (fr) * | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Protéines de liaison recombinantes ayant un domaine effecteur activable |
WO2024104933A1 (fr) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Molécules de liaison à l'antigène |
EP4378529A1 (fr) * | 2022-12-03 | 2024-06-05 | Universitätsklinikum Hamburg-Eppendorf | Anticorps destiné à être utilisé dans une thérapie impliquant une mise en prise de cellules effectrices |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
ES2102007T3 (es) * | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
GB9221657D0 (en) * | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
EP1536005A4 (fr) | 2002-08-16 | 2006-05-17 | Univ Tokyo | Procede d'analyse d'une interaction entre des proteines |
US8158385B2 (en) * | 2002-10-11 | 2012-04-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
EP1561114B1 (fr) * | 2002-11-07 | 2008-05-07 | Erasmus Universiteit Rotterdam | Sondes fret et procedes de detection de molecules d'interaction |
SI1673398T1 (sl) * | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
GB0421836D0 (en) * | 2004-10-01 | 2004-11-03 | Avidex Ltd | T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents |
US8623356B2 (en) * | 2005-11-29 | 2014-01-07 | The University Of Sydney | Demibodies: dimerization-activated therapeutic agents |
CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
CA2734265C (fr) * | 2008-08-20 | 2017-12-19 | Ibc Pharmaceuticals, Inc. | Vaccins d'accostage et de verrouillage « dock-and-lock » (dnl) pour une therapie contre le cancer |
BR112012026766B1 (pt) * | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
-
2013
- 2013-01-14 PL PL13704369T patent/PL2802607T3/pl unknown
- 2013-01-14 NO NO13704369A patent/NO2802607T3/no unknown
- 2013-01-14 EP EP17193746.9A patent/EP3333190A1/fr not_active Ceased
- 2013-01-14 HU HUE13704369A patent/HUE035207T2/en unknown
- 2013-01-14 EA EA201400811A patent/EA033947B1/ru not_active IP Right Cessation
- 2013-01-14 AU AU2013208895A patent/AU2013208895B2/en active Active
- 2013-01-14 DK DK13704369.1T patent/DK2802607T3/en active
- 2013-01-14 WO PCT/EP2013/050603 patent/WO2013104804A2/fr active Application Filing
- 2013-01-14 SI SI201330893T patent/SI2802607T1/en unknown
- 2013-01-14 EP EP21174675.5A patent/EP3907241A1/fr active Pending
- 2013-01-14 CN CN201711383463.0A patent/CN108034006A/zh active Pending
- 2013-01-14 PT PT137043691T patent/PT2802607T/pt unknown
- 2013-01-14 US US14/371,910 patent/US20150079093A1/en not_active Abandoned
- 2013-01-14 SG SG11201403997SA patent/SG11201403997SA/en unknown
- 2013-01-14 CN CN201380012188.5A patent/CN104159923B/zh active Active
- 2013-01-14 LT LTEP13704369.1T patent/LT2802607T/lt unknown
- 2013-01-14 KR KR1020147022652A patent/KR102100817B1/ko active IP Right Grant
- 2013-01-14 EP EP13704369.1A patent/EP2802607B1/fr not_active Revoked
- 2013-01-14 KR KR1020207009766A patent/KR20200040893A/ko not_active IP Right Cessation
- 2013-01-14 RS RS20171357A patent/RS56773B1/sr unknown
- 2013-01-14 MX MX2014008468A patent/MX359411B/es active IP Right Grant
- 2013-01-14 JP JP2014551643A patent/JP6408915B2/ja active Active
- 2013-01-14 ES ES13704369.1T patent/ES2653287T3/es active Active
- 2013-01-14 CA CA2861003A patent/CA2861003C/fr active Active
-
2014
- 2014-07-09 IL IL233566A patent/IL233566B/en active IP Right Grant
- 2014-07-30 ZA ZA2014/05658A patent/ZA201405658B/en unknown
-
2015
- 2015-01-20 HK HK15100628.3A patent/HK1200175A1/xx not_active IP Right Cessation
-
2017
- 2017-12-11 HR HRP20171912TT patent/HRP20171912T1/hr unknown
- 2017-12-21 CY CY20171101342T patent/CY1119928T1/el unknown
-
2019
- 2019-03-01 US US16/289,798 patent/US11427644B2/en active Active
-
2022
- 2022-06-17 US US17/842,915 patent/US20220340681A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200175A1 (en) | Dual antigen-induced bipartite functional complementation | |
GB2504800B (en) | Dishwasher | |
GB2522147B (en) | Dishwasher | |
HK1205668A1 (en) | Cylindrical cooker | |
SG10201505726RA (en) | Accommodation cassette | |
GB2508730B (en) | Dishwasher | |
GB2508731B (en) | Dishwasher | |
HK1214745A1 (zh) | 勺子 | |
AU345199S (en) | Tray | |
HRP20181120T1 (hr) | Sanitarni set | |
HK1189466A1 (zh) | 鞋墊 | |
GB2507355B (en) | Bowls measure | |
PL2653088T3 (pl) | Automatyczna zmywarka do naczyń | |
PL2653087T3 (pl) | Zmywarka do naczyń | |
AU5123P (en) | Sprilecstar Cordyline banksii | |
AU348082S (en) | Toilet | |
AP00440S1 (en) | Toilet | |
AU347046S (en) | Sandals | |
GB201218100D0 (en) | Urinals | |
AU343179S (en) | Tray | |
HK1161507A2 (en) | Insole | |
GB201205008D0 (en) | Pivots | |
GB201202988D0 (en) | Detector |